Analyst RatingAnalyst maintains a BUY rating and raises the 12-month price target to $20.50, indicating a belief in significant upside potential due to Plus Therapeutics' clinical progress and market opportunities.
Diagnostic CommercializationThe upcoming launch of the CNSide platform, a novel diagnostic tool for leptomeningeal metastases, is expected to be a major positive for the stock.
Financial StabilityThe company has a solid balance sheet with $10 million in cash and no debt, and it raised $18 million in Q1, providing enough financial resources into 2026.